Table 4.
circRNAs in cancer
| circRNA name (host gene) | Disease | Species | Study design | Molecular mechanism of circRNA | References |
|---|---|---|---|---|---|
| circRNA abundance | Colorectal and ovarian cancer (protective) | Human | Expression profiling of ovarian cancer cells (n = 16), ascites (n = 8) and cell lines (n = 4). Validation in colorectal cancer/control samples (n = 42) and ovarian cancer/control cells (n = 16) | [210] | |
| circHIPK3 | Colorectal, bladder, breast, liver, gastric, kidney and prostate cancer (deleterious). | Human | Expression profiling in cancer (n = 7) and control tissues (n = 6) and candidate gene approach. Functional analysis in cultured cells in vitro | microRNA sponging | [43] |
| circCCDC66 | Colorectal cancer (deleterious) | Human | Expression profiling and validation in tissue/controls (n = 48 pairs). Biomarker analysis in tissue samples (n = 229). Functional studies. | microRNA sponging | [211] |
| circBANP | Colorectal cancer (deleterious) | Human | Expression profiling of colorectal cancer/control tissue pairs (n = 35). Validation in colorectal cancer cell lines (n = 2) | [212] | |
| Cdr1as | Colorectal cancer (deleterious) | Human | Comparison of colorectal cancer/control tissue samples (n = 197) and validation (n = 165) | microRNA sponging | [213] |
| hsa_circ_001988 (FBXW7) | Colorectal cancer (protective) | Human | Comparison of colorectal cancer/control tissue samples (n = 31) | [214] | |
| hsa_circ_0000069 (STIL) | Colorectal cancer (deleterious) | Human | Expression profiling of colorectal cancer/control tissue pairs (n = 6). Validation in n = 24 | [215] | |
| circ_001569 (ABCC1) | Colorectal cancer (deleterious) | Human | Candidate approach in colorectal cancer/control tissue pairs (n = 30); validation in cell lines (n = 6) | microRNA sponging | [216] |
| circ-ITCH | Colorectal, hepatocellular, lung, and esophageal cancer (protective) | Human | Candidate expression QTL study in Hepatocellular carcinoma (n = 288), lung cancer (n = 78), esophageal carcinoma (n = 684) and colorectal carcinoma (n = 45) | microRNA sponging | [217] [218] [219] [220] |
| circPVT1 | Gastric cancer (deleterious) | Human | Expression profiling in cancer/control tissue pairs (n = 3 each); Validation in paired cancer/controls (n = 20 each). Second validation in cancerous/adjacent noncancerous tissue (n = 187 each) | microRNA sponging | [221] |
| hsa_circ_0000190 (CNIH4) | Gastric cancer (protective) | Human | Candidate approach in gastric cancer/control tissue pairs (n = 104) and of blood plasma of cancer patients/control (n = 104, each) | [222] | |
| hsa_circ_0001649 (SHPRH) | Gastric cancer (protective) | Human | Candidate approach in gastric cancer/control tissue pairs (n = 76). Validation in patient blood serum samples (pre- and post-operation, n = 20) | [223] | |
| circZKSCAN1 | Hepatocellular carcinoma (protective) | Human | Candidate approach in hepatocellular carcinoma/control tissue pairs (n = 102). Validation in human cell lines (n = 5). Functional studies in xenograft mouse model | [224] | |
| hsa_circ_0001649 (SHPRH) | Hepatocellular carcinoma (protective) | Human | Candidate approach hepatocellular carcinoma/control tissue pairs (n = 89) | [225] | |
| hsa_circ_0005075 (EIF4G3) | Hepatocellular carcinoma (deleterious) | Human | Expression profiling in hepatocellular carcinoma/control tissue pairs (n = 3). Validation in hepatocellular carcinoma/control tissue pairs (n = 30) | [226] | |
| circ-TTBK2 | Glioblastoma (deleterious) | Human | Candidate approach in control brain tissues (n = 11) and gliomas (n = 76). Functional analysis in mouse xenograft model in vivo | microRNA sponging | [227] |
| circBRAF | Glioblastoma (protective) | Human | Expression profiling in glioblastoma tissue and normal brain samples (n = 5 each). Validation in glioma patients (n = 68) | [228] | |
| cZNF292 | Glioblastoma (deleterious) | Human | Candidate approach in glioma cell lines (n = 2) | [229] | |
| circTCF25 | Bladder carcinoma (deleterious) | Human | Expression profiling in bladder carcinoma/control tissue pairs (n = 4). Validation in bladder carcinoma/control tissue pairs (n = 40, including 4 from expression profiling) | microRNA sponging | [230] |
| circPVT1 | Lung and breast cancer (deleterious) | Human | Expression profiling and candidate approach in proliferating/senescent WI-38 fibroblasts (n = 38) and in cancer cell lines | microRNA sponging | [231] |
| hsa_circ_0004277 (WDR37) | Acute myeloid leukemia (protective) | Human | Expression profiling of AML patients (n = 6) and controls (n = 4). Validation in AML (n = 107) and control individuals (n = 8) | [232] | |
| hsa_circ_0067934 (PRKCI) | Esophageal carcinoma (deleterious) | Human | Candidate approach in esophageal carcinoma/control tissue pairs (n = 51). Validation in cell lines (n = 5) | [233] | |
| hsa_circRNA_100855/hsa_circRNA_104912 | Laryngeal carcinoma (deleterious/protective) | Human | Expression profiling in laryngeal carcinoma/control tissues (n = 4). Validation in matched cancers/controls (n = 52) | [234] |